The change in a company's future earnings potential, as reflected in earnings estimate revisions, and the near- term price movement of its stock are proven to be strongly correlated. That's partly because of the influence of institutional investors that use earnings and earnings estimates for calculating the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically ...

Individual investors often find it hard to make decisions based on rating upgrades by Wall Street analysts, since these are mostly driven by subjective factors that are hard to see and measure in real time. In these situations, the Zacks rating system comes in handy because of the power of a changing earnings picture in determining near-term stock price movements. As such, the Zacks rating upgrade for Colruyt is essentially a positive comment on its earnings outlook that could have a favorable impact on its ...

Selective Insurance (SIGI) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change. The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate. As such, the Zac ...

Yamaha Motor Co., Ltd. (YMHAY) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following y ...

Nasdaq (NDAQ) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system. The powe ...

Since a changing earnings picture is a powerful factor influencing near-term stock price movements, the Zacks rating system is very useful for individual investors. They may find it difficult to make decisions based on rating upgrades by Wall Street analysts, as these are mostly driven by subjective factors that are hard to see and measure in real time. As such, the Zacks rating upgrade for Ferguson plc is essentially a positive comment on its earnings outlook that could have a favorable impact on its stock ...

核心观点 - 伯克希尔哈撒韦B类股近期市场关注度高，其短期股价表现可能受到盈利预期修正、营收增长预测、历史业绩及估值等因素的综合影响，公司目前的Zacks评级为“买入”，表明其可能在未来一段时间内跑赢大盘 [1][2][18] 近期市场表现 - 过去一个月，公司股价上涨+4%，表现优于同期Zacks S&P 500综合指数+2.1%的涨幅，也跑赢了其所属的Zacks财产与意外险行业同期+5.3%的涨幅 [2] 盈利预期与修正 - 公司的投资决策分析基于卖方分析师对盈利预期的修正，盈利预期上调通常推高股票公允价值并可能带动股价上涨，实证研究表明盈利预期修正趋势与短期股价变动有强相关性 [3][4] - 当前季度每股收益预期为5.53美元，同比增长+7%，过去30天该预期未变 [5] - 当前财年每股收益预期为20.82美元，同比增长+1%，过去30天该预期未变 [5] - 下一财年每股收益预期为21.59美元，同比增长+3.7%，过去一个月该预期未变 [6] - 基于近期共识预期的变化及其他相关因素，公司被评定为Zacks Rank 2（买入） [7] 营收增长预测 - 当前季度营收共识预期为953亿美元，同比增长+3% [11] - 当前财年营收共识预期为3856亿美元，同比增长+3.8% [11] - 下一财年营收共识预期为4049亿美元，同比增长+5% [11] 最近报告业绩与历史超预期情况 - 上一报告季度营收为936.8亿美元，同比增长+4.4%，低于共识预期951亿美元，意外幅度为-1.5% [12] - 上一报告季度每股收益为5.25美元，高于去年同期的4.47美元，并超出共识预期+8.92% [12] - 过去四个季度中，公司有两次每股收益超出市场共识预期 [13] 估值分析 - 公司的估值通过Zacks价值风格评分进行评估，该评分综合了传统和非传统估值指标 [16] - 公司在该评分中获得C级，表明其估值水平与同业公司相当 [17]

股价表现与交易量 - Bioventus (BVS) 股价在上一交易日收于11.78美元，大幅上涨12.4% [1] - 股价上涨伴随着可观的交易量，当日换手股数高于平均水平 [1] - 过去四周，该股累计上涨15.9% [1] 业绩预期与财务数据 - Bioventus 即将发布的季度报告预计每股收益(EPS)为0.21美元，与去年同期持平 [2] - 预计季度营收为1.5453亿美元，较去年同期增长4.7% [2] - 过去30天内，市场对该公司本季度的共识EPS预期保持不变 [3] 业务与行业表现 - 股价上涨源于投资者对公司关键业务板块销售表现的信心增强，这些板块包括疼痛治疗、手术解决方案和修复疗法 [1] - Bioventus 所属的Zacks行业分类为医疗-药物行业 [4] - 同行业公司Rigel Pharmaceuticals (RIGL) 上一交易日收于40.26美元，上涨4% [4] - 过去一个月，Rigel Pharmaceuticals 的股价回报率为29.4% [4] 同行比较与评级 - Rigel Pharmaceuticals 对即将发布报告的共识EPS预期在过去一个月保持不变，为0.91美元 [5] - 与去年同期EPS相比，Rigel Pharmaceuticals 的预期EPS变化为下降72.3% [5] - Bioventus 目前获得Zacks排名第2名(买入) [4] - Rigel Pharmaceuticals 目前获得Zacks排名第5名(强烈卖出) [5]